NCT02499562View on ClinicalTrials.gov

A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

June 25, 2015

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Hydronidone

The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.

DRUG

Placebo

DRUG

Entecavir

Trial Locations (2)

Unknown

Shanghai General Hospital, Shanghai

Beijing

All Listed Sponsors
lead

Shanghai Genomics, Inc.

INDUSTRY

NCT02499562 - A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis | Biotech Hunter | Biotech Hunter